Chronic yeast infections, clinically called recurrent vulvovaginal candidiasis, are defined as three or more symptomatic episodes within a single year. This affects fewer than 5% of women, but for those dealing with it, the cycle of itching, burning, and discharge can feel relentless. Treatment goes beyond the single-dose antifungal you’d pick up at the pharmacy. It typically involves an initial course to clear the active infection followed by months of maintenance therapy to keep yeast from bouncing back.
Why Confirming the Diagnosis Matters
If your infections keep returning, the first step is making sure yeast is actually the culprit. Symptoms like itching, irritation, and thick discharge overlap with bacterial vaginosis and other vaginal infections, and studies show that self-diagnosis is wrong roughly half the time. A provider can examine vaginal discharge under a microscope to look for yeast cells, but if that test comes back negative while symptoms persist, a vaginal culture or PCR test is the next move.
Getting a culture is especially important for recurrent cases because it identifies the exact species of yeast involved. Most yeast infections are caused by Candida albicans, which responds well to standard antifungal medications. But a meaningful percentage of recurrent infections involve other species, particularly Candida glabrata, which is naturally resistant to the most commonly prescribed treatments. Knowing which species you’re dealing with changes the entire treatment plan.
Standard Maintenance Therapy
The backbone of treatment for recurrent yeast infections is a two-phase approach: first, clear the current infection with a short course of antifungal medication (typically taken over one to two weeks), then follow it with a longer maintenance phase where you take a lower dose weekly for six months. This extended schedule keeps yeast populations suppressed long enough to break the cycle of recurrence.
This approach works well for most people while they’re on it. The challenge is what happens after maintenance ends. A significant number of women experience another infection within the first few months of stopping. That doesn’t mean the treatment failed. It often means the underlying conditions driving the overgrowth haven’t been fully addressed, which is why identifying and managing risk factors (more on that below) is just as important as the medication itself.
A Newer Oral Option
In 2022, the FDA approved oteseconazole (brand name Vivjoa), the first medication specifically designed for preventing recurrent yeast infections. It works similarly to older antifungals but stays active in the body longer, which makes it effective as a once-weekly maintenance pill. Treatment lasts about 11 to 14 weeks total, depending on the regimen your provider chooses.
There’s one important caveat: Vivjoa is only approved for people who are not of reproductive potential, meaning those who are postmenopausal, have had a hysterectomy, or are otherwise unable to become pregnant. The medication poses risks during pregnancy, so it’s not an option for anyone who could conceive. For those who do qualify, clinical trials showed it significantly reduced the rate of recurrence compared to placebo over a full year.
Boric Acid for Resistant Infections
When standard antifungals don’t work, particularly in infections caused by Candida glabrata or other resistant species, boric acid vaginal suppositories are a well-supported second-line option. The typical protocol is a 600 mg suppository inserted vaginally once daily for 14 days. For ongoing prevention, a systematic review published in 2024 suggests continuing with 600 mg twice weekly as maintenance, though the ideal length of that maintenance phase isn’t firmly established yet.
Boric acid is not a fringe remedy. It has decades of clinical use behind it, and researchers have recommended it as a first-choice treatment specifically for azole-resistant yeast infections. It’s available over the counter in suppository form. That said, it should only be used vaginally, never taken by mouth, as it is toxic if swallowed.
Addressing the Root Causes
Medication controls yeast overgrowth, but if you’re not addressing the factors that create a hospitable environment for it, infections tend to return. The most significant modifiable risk factor is blood sugar control. Elevated blood glucose, whether from diabetes or consistently high sugar intake, directly feeds yeast growth. High glucose raises vaginal glycogen levels, which lowers vaginal pH and creates conditions where Candida species thrive. Research shows that 18.8% of people with diabetes have vaginal Candida colonization compared to 11.8% of those without diabetes, and women with recurrent yeast infections tend to have higher average blood sugar levels overall.
If you have diabetes, tightening your blood sugar management can meaningfully reduce yeast recurrence. Even without a diabetes diagnosis, paying attention to blood sugar spikes from a heavily refined-carbohydrate diet may help. Other well-established risk factors include recent antibiotic use (which wipes out protective vaginal bacteria along with the targeted infection), immunosuppression from conditions like HIV, and hormonal changes.
What About Probiotics?
Probiotics containing Lactobacillus strains are increasingly studied as a way to restore and maintain the protective bacterial environment in the vagina. Clinical trials have shown that certain strains, including L. rhamnosus, L. crispatus, and L. reuteri, can reduce pathogenic organisms and increase beneficial lactobacilli within 10 days of use, with the improved balance holding steady for at least 30 days after stopping. Multiple trials suggest that both oral and vaginal probiotic administration hold promise for preventing recurrence of yeast infections.
The evidence is encouraging but still developing. Probiotics are best thought of as a complement to antifungal treatment rather than a replacement. If you want to try them, look for products that contain well-studied strains at colony counts in the billions, and consider them part of a broader prevention strategy alongside blood sugar management and maintenance antifungal therapy.
Does Your Partner Need Treatment?
This is a question that comes up often, and the answer for yeast infections specifically is less clear-cut than you might expect. In late 2025, the American College of Obstetricians and Gynecologists recommended partner treatment for the first time for recurrent bacterial vaginosis, citing strong new evidence that sexual activity drives BV recurrence. But for recurrent yeast infections, guidelines have not made the same recommendation. Current evidence doesn’t show a consistent benefit from treating male sexual partners to prevent yeast recurrence in women.
That said, if your partner is experiencing symptoms of their own, such as redness, itching, or irritation on the penis, they should be evaluated and treated independently. The lack of a blanket recommendation for partner treatment doesn’t mean sexual transmission never plays a role. It means the data hasn’t been strong enough to make it standard practice yet.
What a Realistic Treatment Timeline Looks Like
If you’re just starting treatment for recurrent yeast infections, expect a process that spans months, not days. The initial clearing phase takes one to two weeks. Maintenance therapy runs for six months with traditional antifungals, or roughly three months with newer options like Vivjoa. During maintenance, most people are symptom-free. The real test comes after you stop: the first three to six months off treatment is when recurrence is most likely.
If infections return after completing a full maintenance course, your provider may recommend a longer maintenance period, switch to a different medication class, or investigate whether a resistant yeast species is involved. Getting a culture at that point, if one wasn’t done earlier, becomes essential. For infections caused by resistant species, boric acid maintenance can be continued longer-term with periodic check-ins. Treating recurrent yeast infections is often an iterative process, but the combination of targeted antifungal therapy, species identification, and risk factor management gives most people a path to lasting relief.